Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT06381778
Recruiting Observational

Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis

NCT06381778 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Far Eastern Memorial Hospital
Phase
Observational
Started
2023-02-06
Last updated
2024-07-26

Condition(s) studied

Hypertrophic Cardiomyopathy

Study summary

Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific "red-flag" signs of Fabry disease in Taiwan.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Presence of left ventricular hypertrophy (LVH) on echo/CMRI: 2. maximal interventricular septal (IVST) and/or posterior wall thickness (PWT) ≥13 mm, 3. apical wall thickness ≥15 mm or a ratio of apical to basal LV wall thickness of ≥ 1.3 at end-diastole, OR 4. maximal LV wall thickness ≥ 15mm of ANY OTHER PART 5. Male and female adult age ≥ 20 year-old 6. Patients willing to comply with and sign the informed consent Exclusion Criteria: 1. Patients refuse or unable to give informed consent 2. Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program 3. Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload 4. Athletic heart 5. Non-compaction cardiomyopathy

Primary outcome measure(s)

  • Death — 1 year
    Death

Trial sites (1)

FacilityCityRegionStatus
Far Eastern Memorial Hospital New Taipei City Taiwan Recruiting

More Far Eastern Memorial Hospital trials in Taiwan

Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction Recruiting
Treatment Efficacy for Overactive Bladder: Comparing Education, Biofeedback, and Nerve Stimulation Starting soon
Maternal Methyl-Nutrient Status and Infant Neurodevelopment Study Recruiting
A Multi-center Cardiac PYP Scan Registry in Taiwan Recruiting
Clinical Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06381778 on ClinicalTrials.gov ↗ ← All trials in Taiwan